Table 2. Clinical costs during the period 1991–2010, 2011–2059 and 1991–2059 according to NHS and Societal perspective in the no-vaccination and vaccination scenario.
| PAST COSTS (1991–2010) | ||||
|---|---|---|---|---|
| NHS perspective | ||||
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 572,051,723 | 362,160,953 | 209,890,771 | 37 |
| CHB | 649,157,949 | 210,059,569 | 439,098,380 | 68 |
| CC | 18,485,689 | 8,914,521 | 9,571,168 | 52 |
| DC | 1,193,807 | 575,700 | 618,107 | 52 |
| HCC | 8,330,359 | 2,830,361 | 5,499,999 | 66 |
| LT | 3,135,545 | 1,117,773 | 2,017,771 | 64 |
| Total | 1,252,355,072 | 585,658,877 | 666,696,195 | 53 |
| Societal perspective | ||||
|---|---|---|---|---|
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 689,926,159 | 436,786,229 | 253,139,930 | 37 |
| CHB | 763,780,696 | 247,150,087 | 516,630,609 | 68 |
| CC | 21,749,733 | 10,488,571 | 11,261,162 | 52 |
| DC | 1,404,599 | 677,353 | 727,247 | 52 |
| HCC | 9,801,263 | 3,330,121 | 6,471,141 | 66 |
| LT | 3,681,249 | 1,311,056 | 2,370,193 | 64 |
| Total | 1,490,343,698 | 699,743,417 | 790,600,281 | 53 |
| FUTURE COSTS (2011–2059) | ||||
|---|---|---|---|---|
| NHS perspective | ||||
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 0 | 0 | 0 | 0 |
| CHB | 1,407,135,406 | 312,317,653 | 1,094,817,753 | 78 |
| CC | 19,147,161 | 8,519,755 | 10,627,406 | 56 |
| DC | 795,200 | 342,980 | 452,219 | 57 |
| HCC | 61,994,027 | 16,534,566 | 45,459,461 | 73 |
| LT | 5,855,495 | 1,471,071 | 4,384,425 | 75 |
| Total | 1,494,927,289 | 339,186,025 | 1,155,741,264 | 77 |
| Societal perspective | ||||
|---|---|---|---|---|
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 0 | 0 | 0 | 0 |
| CHB | 1,655,595,315 | 367,464,028 | 1,288,131,288 | 78 |
| CC | 22,528,002 | 10,024,100 | 12,503,902 | 56 |
| DC | 935,609 | 403,541 | 532,069 | 57 |
| HCC | 73,523,198 | 19,623,408 | 53,899,790 | 73 |
| LT | 6,546,747 | 1,625,042 | 4,921,705 | 75 |
| Total | 1,759,128,872 | 399,140,118 | 1,359,988,754 | 77 |
| TOTAL COSTS (1991–2059) | ||||
|---|---|---|---|---|
| NHS perspective | ||||
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 572,051,723 | 362,160,953 | 209,890,771 | 37 |
| CHB | 2,056,293,355 | 522,377,222 | 1,533,916,133 | 75 |
| CC | 37,632,849 | 17,434,276 | 20,198,573 | 54 |
| DC | 1,989,007 | 918,681 | 1,070,326 | 54 |
| HCC | 70,324,386 | 19,364,927 | 50,959,459 | 72 |
| LT | 8,991,040 | 2,588,844 | 6,402,196 | 71 |
| Total | 2,747,282,361 | 924,844,902 | 1,822,437,459 | 66 |
| Societal perspective | ||||
|---|---|---|---|---|
| No-vaccination | Vaccination | Avoided costs | % reduction | |
| AHB | 689,926,159 | 436,786,229 | 253,139,930 | 37 |
| CHB | 2,419,376,011 | 614,614,115 | 1,804,761,896 | 75 |
| CC | 44,277,735 | 20,512,671 | 23,765,064 | 54 |
| DC | 2,340,208 | 1,080,893 | 1,259,315 | 54 |
| HCC | 83,324,461 | 22,953,529 | 60,370,932 | 72 |
| LT | 10,227,996 | 2,936,098 | 7,291,898 | 71 |
| Total | 3,249,472,570 | 1,098,883,535 | 2,150,589,035 | 66 |
Note: costs assessed during 2011–59 are limited to those that acquired HBV during the 1991–2010 period.